X
19Jul

FDA Releases ZIKV Guidance and Grifols ZIKV Assay Licensed- 1st Update

0 Comments | | Return |

This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.

Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications

Related

MD Revised Headers on CTS forms

Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...

Read More >

Convalescent Plasma Testing for COVID-19

CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...

Read More >

Join us for a Babesia webinar!

As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...

Read More >

Daylight Saving Time Begins March 10

Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...

Read More >

Update on CTS Implementation of the Grifols Procleix Ultrio Elite Assay

In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...

Read More >

Pooled Zika Testing and New CTS Website Functionality- November 29th Update

As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...

Read More >

Subscribe here to receive CTS updates!

Name